LungClear™ is a molecular screening solution that evaluates circulating microRNA biomarkers associated with lung cancer risk. Developed to support early detection, LungClear™ enables clinicians to stratify risk before escalation to imaging modalities such as low-dose CT (LDCT).
Unlike traditional screening approaches that focus primarily on heavy smokers, LungClear™ is designed to assess risk across a broader population, including individuals aged 40 and above, regardless of smoking history. Integrated within a structured referral pathway, the test supports informed clinical decision-making and optimised utilisation of imaging resources.
